ArticleOpen veterinary journal2025
Characterization of the immune response to recombinant GRA-4 protein (rGRA-4) of
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aim: This study aimed to characterize the immune response to recombinant GRA-4 protein (rGRA-4) of Methods: The samples used in this study included splenic organs from six 2-month-old male Result: The results of the study using B cell proliferation analysis with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) showed that the optical density (OD) value obtained was different in each treatment. Treatment with a combination of LPS and GRA-4 protein showed the highest results at a concentration of 10 µg/ml. The results of microscopic examination with 400× magnification showed that the number of T cells stained with MTT was greater in treatment group 2 (added PHA and GRA-4 protein (T lymphocyte proliferation) and treatment group 3 [added lipopolysaccharide (LPS) and GRA-4 protein (B lymphocyte proliferation) compared to treatment group 1 added Conclusion: The results of this study indicate that recombinant rGRA-4 protein has potential as a vaccine candidate to protect the host against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.